People News

BioTime Appoints Industry Veteran, Stephana Patton, Ph.D., J.D., as General Counsel

3.0 from 2 votes
Tuesday, February 07, 2017

BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, announced the appointment of Stephana Patton, Ph.D., J.D., as General Counsel, a newly created position.

Reporting in her new role to Adi Mohanty, Co-CEO, Dr. Patton will oversee all legal matters at the company.

"I am pleased to welcome Stephana to BioTime at this important time," stated Mr. Mohanty. "She brings a breadth and depth of legal experience and expertise in the biopharmaceutical industry and will make important contributions as we continue to simplify our corporate structure, advance our clinical development programs, report additional human data, leverage our sizeable intellectual property portfolio, and prepare for commercialization."

Dr. Patton brings more than 17 years of experience creating portfolio value at publicly-traded biotechnology and pharmaceutical companies. Dr. Patton was formerly the General Counsel and Commercial Compliance Officer at BioDelivery Sciences, a publicly-traded specialty pharmaceutical company. Prior to BioDelivery Sciences, she held various senior management positions, including leading Intellectual Property (IP) and Licensing at Salix Pharmaceuticals, a global pharmaceutical company that was acquired for $11.2 Billion in 2015. Prior to joining Salix, Dr. Patton was in private practice at a large international law firm known for its IP and corporate securities practices. Her practice focused on counseling clients on IP-related matters as well as licensing transactions for biotechnology and pharmaceutical companies at varying stages of product development. Dr. Patton earned a Juris Doctor (J.D.) degree from the Boston University School of Law and a Ph.D. in Biochemistry, Cell and Developmental Biology from Emory University.

"I am thrilled to join the outstanding team at BioTime," said Dr. Patton. "The company is well positioned with exciting clinical programs in aesthetics and ophthalmology that address multi-billion dollar global market opportunities. I look forward to working with the entire team to drive our continued success."

About BioTime

BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. The foundation of BioTime's core therapeutic technology platform is pluripotent cells. Pluripotent cells are capable of becoming any of the cell types in the human body. Pluripotent cells have potential application in many areas of medicine with large unmet patient needs, including various age-related degenerative diseases and degenerative conditions for which there presently are no cures. Unlike pharmaceuticals that require a molecular target, therapeutic strategies based on the use of pluripotent cells are generally aimed at regenerating or replacing affected cells and tissues, and therefore may have broader applicability than pharmaceutical products.

Source: BioTime, Inc.
3.0 from 2 votes
Free Newsletter
Trending News